Xenotransplantation and porcine cytomegalovirus

Xenotransplantation

Volumn 22, Issue 5, 2015, Pages 329-335

  Denner, Joachim ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

herpesviruses porcine cytomegalovirus; virus safety of xenotransplantation; xenotransplantation

Indexed keywords

DNA;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA VIRUS; GRAFT RECIPIENT; GRAFT REJECTION; MICROORGANISM; NONHUMAN; ORGAN; PATHOGENICITY; PIG; PRIMATE; PRIORITY JOURNAL; RECIPIENT; REVIEW; SENSITIVITY ANALYSIS; SURVIVAL TIME; TISSUES; VIRUS LOAD; XENOTRANSPLANTATION; ANIMAL; GENETICS; HUMAN; POSTOPERATIVE COMPLICATIONS; ROSEOLOVIRUS INFECTIONS; TRANSGENIC ANIMAL; TRANSMISSION; VIROLOGY; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; POSTOPERATIVE COMPLICATIONS; ROSEOLOVIRUS INFECTIONS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84941912570     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12180     Document Type: Review

References (53)

1. Gu W, Zeng N, Zhou L, et al., Genomic organization and molecular characterization of porcine cytomegalovirus. Virology 2014; 460: 165-172.
2. Edington N,. Porcine cytomegalovirus. In:, Straw BE, Allaire SD, Mengeling WL, Taylor DJ, eds. Diseases of Swine. Ames, IA: Iowa State University Press, 1999: 125-131.
3. Mueller NJ, Barth RN, Yamamoto S, et al., Activation of cytomegalovirus in pig-to-primate organ xenotransplantation. J Virol 2002; 76: 4734-4740.
4. Widen F, Goltz M, Wittenbrink N, et al., Identification and sequence analysis of the glycoprotein B gene of porcine cytomegalovirus. Virus Genes 2001; 23: 339-346. Erratum in: Virus Genes 2002; 24: 197.
5. Liu X, Liao S, Zhu L, Xu Z, Zhou Y,. Molecular Epidemiology of Porcine Cytomegalovirus (PCMV) in Sichuan Province, China: 2010-2012. PLoS One 2013; 8: e64648.
6. Mueller NJ, Fishman JA,. Herpesvirus infections in xenotransplantation: pathogenesis and approaches. Xenotransplantation 2004; 11: 486-490 Review.
7. Clark DA, Fryer JF, Tucker AW, et al., Porcine cytomegalovirus in pigs being bred for xenograft organs: progress towards control. Xenotransplantation 2003; 10: 142-148.
8. Fishman JA,. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant 2013; 13 (Suppl 3): 1-8; quiz 8.
9. Griffiths PD, Clark DA, Emery VC,. Betaherpesviruses in transplant recipients. J Antimicrob Chemother 2000; 45 (Suppl T3): 29-34.
10. Ramanan P, Razonable RR,. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother 2013; 45: 260-271.
11. Nashan B, Gaston R, Emery V, et al., Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075-1085.
12. Lowance D, Neumayer HH, Legendre CM, et al., Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470.
13. Griffiths P, Lumley S,. Cytomegalovirus. Curr Opin Infect Dis 2014; 27: 554-559.
14. Whitley RJ,. Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 2004; 549: 155-160.
15. Dollard SC, Grosse SD, Ross DS,. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007; 17: 355-363.
16. Michaels MG, Jenkins FJ, St George K, et al., Detection of infectious baboon cytomegalovirus after baboon-to-human liver xenotransplantation. J Virol 2001; 75: 2825-2828.
17. Michaels MG, Alcendor DJ, St George K, et al., Distinguishing baboon cytomegalovirus from human cytomegalovirus: importance for xenotransplantation. J Infect Dis 1997; 176: 1476-1483.
18. Yoshikawa T,. Human herpesvirus 6 infection in hematopoietic stem cell transplant patients. Br J Haematol 2004; 124: 421-432.
19. Tesini BL, Epstein LG, Caserta MT,. Clinical impact of primary infection with roseoloviruses. Curr Opin Virol 2014; 9: 91-96.
20. Schuurman HJ,. Commentary on "Characterization of acid and non-acid glycosphingolipids of porcine heart valve cusps as potential immune targets in biological heart valve grafts" (by Barone et al.): bioprosthetic products from animal origin are xenotransplantation products with their own regulatory path. Xenotransplantation 2014; 21: 507-509.
21. Sekijima M, Waki S, Sahara H, et al., Results of life-supporting galactosyltransferase knockout kidneys in cynomolgus monkeys using two different sources of galactosyltransferase knockout swine. Transplantation 2014; 98: 419-426.
22. Plowright W, Edington N, Watt RG,. The behaviour of porcine cytomegalovirus in commercial pig herds. J Hyg (Lond) 1976; 76: 125-135.
23. Edington N, Watt RG, Plowright W,. Experimental transplacental transmission of porcine cytomegalovirus. J Hyg (Lond) 1977; 78: 243-251.
24. Edington N, Broad S, Wrathall AE, Done JT,. Superinfection with porcine cytomegalovirus initiating transplacental infection. Vet Microbiol 1988; 16: 189-193.
25. Liu X, Xu Z, Zhu L, Liao S, Guo W,. Transcriptome analysis of porcine thymus following porcine cytomegalovirus infection. PLoS One 2014; 9: e113921.
26. Degré M, Ranneberg-Nilsen T, Beck S, Rollag H, Fiane AE,. Human cytomegalovirus productively infects porcine endothelial cells in vitro. Transplantation 2001; 72: 1334-1337.
27. Huang CA, Fuchimoto Y, Gleit ZL, et al., Posttransplantation lymphoproliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: similarity to human PTLD and association with a porcine gammaherpesvirus. Blood 2001; 97: 1467-1473.
28. Whitteker JL, Dudani AK, Tackaberry ES,. Human fibroblasts are permissive for porcine cytomegalovirus in vitro. Transplantation 2008; 86: 155-162.
29. Gollackner B, Mueller NJ, Houser S, et al., Porcine cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation. Transplantation 2003; 75: 1841-1847.
30. Mueller NJ1, Kuwaki K, Dor FJ, et al., Reduction of consumptive coagulopathy using porcine cytomegalovirus-free cardiac porcine grafts in pig-to-primate xenotransplantation. Transplantation 2004; 78: 1449-1453.
31. Yamada K, Tasaki M, Sekijima M, et al., Porcine cytomegalovirus infection is associated with early rejection of kidney grafts in a pig to baboon xenotransplantation model. Transplantation 2014; 98: 411-418.
32. Byrne GW, Logan JS, McGregor CG,. Prevention, detection, and management of early bacterial and fungal infections in a preclinical cardiac xenotransplantation model that achieves prolonged survival. Xenotransplantation 2005; 12: 127-133.
33. Wynyard S, Nathu D, Garkavenko O, Denner J, Elliott R,. Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. Xenotransplantation 2014; 21: 309-323.
34. Abrahante JE, Martins K, Papas KK, et al., Microbiological safety of porcine islets: comparison with source pig. Xenotransplantation 2011; 18: 88-93.
35. Sachs DH,. The pig as a potential xenograft donor. Vet Immunol Immunopathol 1994; 43: 185-191.
36. Shimatsu Y, Yamada K, Horii W, et al., Production of cloned NIBS (Nippon Institute for Biological Science) and α-1, 3-galactosyltransferase knockout MGH miniature pigs by somatic cell nuclear transfer using the NIBS breed as surrogates. Xenotransplantation 2013; 20: 157-164.
37. Nunoya T, Shibuya K, Saitoh T, et al., Use of miniature pig for biomedical research, with reference to toxicologic studies. J Toxicol Pathol 2007; 20: 125-132.
38. Fryer JF, Griffiths PD, Emery VC, Clark DA,. Susceptibility of porcine cytomegalovirus to antiviral drugs. J Antimicrob Chemother 2004; 53: 975-980.
39. Mueller NJ, Sulling K, Gollackner B, et al., Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation. Am J Transplant 2003; 3: 1057-1064.
40. Denner J,. Xenotransplantation and Hepatitis E virus. Xenotransplantation 2015; 22: 167-173.
41. Emery VC,. Progress in understanding cytomegalovirus drug resistance. J Clin Virol 2001; 21: 223-228.
42. Boeckh M, Murphy WJ, Peggs KS,. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 2015; 21: 24-29.
43. Kern ER,. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res 2006; 71: 164-171.
44. Prichard MN, Kern ER,. The search for new therapies for human cytomegalovirus infections. Virus Res 2011; 157: 212-221.
45. Schleiss MR,. Developing a vaccine against Congenital Cytomegalovirus (CMV) infection: what have we learned from animal models? where should we go next? Future Virol 2013; 8: 1161-1182.
46. Pass RF, Zhang C, Evans A, et al., Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360: 1191-1199.
47. Griffiths PD, Stanton A, Mccarrell E, et al., Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256-1263.
48. Sabbaj S, Pass RF, Goepfert PA, Pichon S,. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 2011; 203: 1534-1541.
49. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al., A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Infect Dis 2012; 12: 290-299.
50. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al., Reanalysis of TransVax immunogenicity. Lancet Infect Dis 2013; 13: 18.
51. Sung H, Schleiss MR,. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010; 9: 1303-1314.
52. Heineman TC, Schleiss M, Bernstein DI, et al., A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006; 193: 1350-1360.
53. Liu X, Zhu L, Shi X, et al., Indirect-blocking ELISA for detecting antibodies against glycoprotein B (gB) of porcine cytomegalovirus (PCMV). J Virol Methods 2012; 186: 30-35.